- Personal FinanceCompare Online BrokersTop StocksAlternative Investing
- CryptoGet StartedNFTs
Beam Therapeutics (NASDAQ:BEAM), Quotes and News Summary
Beam Therapeutics (NASDAQ: BEAM)
Earnings
see more| Q3 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-11-07 | ||||||
| REV | |||||||
| Q2 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.080 | -1.020 | 0.0600 | ||||
| REV | 8.390M | 16.652M | 8.262M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
Beam Therapeutics Questions & Answers
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Other companies in Beam Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), Ultragenyx Pharmaceutical (NASDAQ:RARE), Cerevel Therapeutics Hldg (NASDAQ:CERE), Fate Therapeutics (NASDAQ:FATE) and Mirati Therapeutics (NASDAQ:MRTX).
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Barclays on Wednesday, August 10, 2022. The analyst firm set a price target for 60.00 expecting BEAM to rise to within 12 months (a possible 5.91% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $56.65 last updated Today at August 18, 2022, 5:06 PM UTC.
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 7, 2022.
There is no upcoming split for Beam Therapeutics.
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.